Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2021
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid TumorsNiharika B Mettu, Susanna V Ulahannan, Johanna C Bendell, et al.
Investigational New Drugs|October 11, 2018
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancerG Weldon Gilcrease, David D Stenehjem, Mark L Wade, et al.
Eclinicalmedicine|January 11, 2024
Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021)Daneng Li, Yohann Loriot, Adam M Burgoyne, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|September 7, 2018
Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative ChemotherapyDouglas S Swords, Samual R Francis, Shane Lloyd, et al.
Cancers|April 13, 2024
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic CancerFaithlore P Gardner, Zev A Wainberg, Christos Fountzilas, et al.
Plos One|February 22, 2020
The stochastic nature of errors in next-generation sequencing of circulating cell-free DNADavid A Nix, Sabine Hellwig, Christopher Conley, et al.
Immunotherapy|September 12, 2024
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumorsBen Tran, Mark Voskoboynik, Johanna Bendell, et al.
Molecular Cancer Therapeutics|December 8, 2010
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancerMaria C Villarroel, N V Rajeshkumar, Ignacio Garrido-Laguna, et al.
Neoplasia (New York, N.Y.)|July 23, 2021
Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinomaKajsa E Affolter, Sabine Hellwig, David A Nix, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2014
Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in UtahN Jewel Samadder, Karen Curtin, Jathine Wong, et al.
Pageof 11